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ABSTRACT
Objectives: Risk scores are recommended in
guidelines to facilitate the management of patients who
present with acute coronary syndromes (ACS).
Internationally, such scores are not systematically used
because they are not easy to apply and some risk
indicators are not available at first presentation. We
aimed to derive and externally validate a more accurate
version of the Global Registry of Acute Coronary
Events (GRACE) risk score for predicting the risk of
death or death/myocardial infarction (MI) both acutely
and over the longer term. The risk score was designed
to be suitable for acute and emergency clinical settings
and usable in electronic devices.
Design and setting: The GRACE risk score (2.0) was
derived in 32 037 patients from the GRACE registry
(14 countries, 94 hospitals) and validated externally in
the French registry of Acute ST-elevation and non-ST-
elevation MI (FAST-MI) 2005.
Participants: Patients presenting with ST-elevation
and non-ST elevation ACS and with long-term
outcomes.
Outcome measures: The GRACE Score (2.0)
predicts the risk of short-term and long-term mortality,
and death/MI, overall and in hospital survivors.
Results: For key independent risk predictors of death
(1 year), non-linear associations (vs linear) were found
for age (p<0.0005), systolic blood pressure
(p<0.0001), pulse (p<0.0001) and creatinine
(p<0.0001). By employing non-linear algorithms, there
was improved model discrimination, validated
externally. Using the FAST-MI 2005 cohort, the c
indices for death exceeded 0.82 for the overall
population at 1 year and also at 3 years. Discrimination
for death or MI was slightly lower than for death alone
(c=0.78). Similar results were obtained for hospital
survivors, and with substitutions for creatinine and
Killip class, the model performed nearly as well.
Conclusions: The updated GRACE risk score has
better discrimination and is easier to use than the
previous score based on linear associations. GRACE
Risk (2.0) performed equally well acutely and over the
longer term and can be used in a variety of clinical
settings to aid management decisions.
INTRODUCTION
Acute coronary syndromes (ACSs) comprise
a heterogeneous spectrum of patients who
are currently stratiﬁed for management
mainly on the basis of ECG characteristics
Strengths and limitations of this study
▪ The Global Registry of Acute Coronary Events
(GRACE) 2.0 risk score is derived from the
largest multinational registry in acute coronary
syndromes (ACS) and validated in an entirely
independent dataset with comprehensive long-
term outcome data.
▪ This risk score employs non-linear functions and
is more accurate than the original version. It is
now validated over the longer term (to 1 and
3 years) and with substitutions possible for cre-
atinine values and Killip class (performing
almost as well).
▪ This electronic risk score is designed to be used
in mobile electronic devices (approximately 30 s
to enter data) and presents the risk of death (or
death/myocardial infarction) and relative to the
entire ACS population.
▪ The score is designed to assist clinical manage-
ment decisions and is not a substitute for indi-
vidual patient clinical assessment. However, it
may help to address the current ‘treatment-risk
paradox’ whereby low-risk rather than high-risk
patients are more likely to receive interventional
therapies.
▪ Additional factors may influence outcome, espe-
cially in geographical populations and healthcare
systems not evaluated in the multinational
GRACE programme.
Fox KAA, FitzGerald G, Puymirat E, et al. BMJ Open 2014;4:e004425. doi:10.1136/bmjopen-2013-004425 1
Open Access Research
group.bmj.com on May 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
and biomarker results. National Institute for Health and
Care Excellence (NICE), Scottish Intercollegiate
Guidelines Network (SIGN), European Society of
Cardiology (ESC) and North American guidelines separ-
ate patients into ST-elevation MI or non-ST-elevation
ACS, and they also recommend use of a risk score such
as the Global Registry of Acute Coronary Events
(GRACE) score.1–4 However, systematic risk stratiﬁcation
is not widely performed, despite the evidence and the
guidelines.
WHY SHOULD RISK ASSESSMENT BE IMPORTANT FOR
THE TRIAGE AND MANAGEMENT OF PATIENTS WITH
ACUTE CORONARY DISEASE?
Whether a patient proceeds to an immediate, urgent or
delayed coronary angiography and revascularisation and
which of the acute antithrombotic regimens is chosen
depends on patient risk characteristics. Evidence from
randomised trials and guideline recommendations all
support the use of different strategies according to risk
status.1–4
In the development of NICE guideline 94 (http://
www.nice.org/cg94), the guideline states that single vari-
ables (eg, troponin) were not as good as multiple vari-
ables in predicting outcome.1 NICE independently tested
all of the published risk scores (GRACE,5 6 TIMI,7
PURSUIT,8 PREDICT,9 EMMACE,10 SRI,11 AMIS,12 UA13
risk score) in 64 312 patients from the MINAP dataset.
They employed a ‘mini-GRACE score’ as many of the
MINAP patients lacked creatinine values and Killip classi-
ﬁcation (substituting a history of renal dysfunction and
the use of diuretics) and this approach also demonstrated
good performance in an independent assessment.14 The
c statistics was 0.825 with 95% conﬁdence bounds 0.82 to
0.83 and this was superior to the performance of the
other risk scores, and hence the recommendation from
NICE to employ the GRACE risk score.1 However, the use
of substitutions for creatinine and for Killip class has not
been validated in an independent dataset and the predic-
tion of long-term outcome had not been tested. In add-
ition, non-linear functions for continuous variables and
for Killip class may improve model discrimination and
could be implemented in hand-held electronic devices.
RESOLVING THE ‘TREATMENT-RISK PARADOX’
We and others have revealed a treatment-risk paradox in
the management of acute coronary disease.15 16 In con-
trast to the evidence and the guideline recommenda-
tions, lower risk rather than higher risk patients are
more likely to undergo interventional procedures and
receive more aggressive antithrombotic and other ther-
apies.15 16 This phenomenon has now been reported
across widely different healthcare systems and different
geographical settings. Why is this? First, current treat-
ment decisions rely on clinical assessment and it is difﬁ-
cult for the clinician to weigh up potential beneﬁts
against potential hazards, and hence lower risk patients
are commonly selected for more aggressive treatment
(an unintended risk-averse approach). However, evi-
dence demonstrates that even excluding those with con-
traindications, higher risk cohorts potentially have more
to gain.15
WHY ARE RISK SCORES NOT MORE WIDELY USED?
Internationally, risk scores are not systematically applied
for the management of ACS despite the evidence and
guideline recommendations. Several factors contribute
to this, including the misperception that clinician assess-
ment or the use of individual risk indicators is sufﬁ-
cient.1 2 17 In addition, the most accurate risk scores
have been cumbersome to compute (eg, requiring
look-up tables and many use arbitrary score results).
Finally, the parameters necessary for their implementa-
tion may not be available at the time of the patient’s
initial presentation.
WHAT THIS STUDY ADDS?
We aimed to develop and validate a revised and more
accurate version of the GRACE risk score suitable for
the acute and long-term prediction of risk. Instead of
assuming that continuous variables such as age and the
categorical variable Killip class were linearly associated
with risk, we tested for non-linear associations and
included them in the revised prediction tool where
appropriate. In contrast to the earlier version of the
GRACE score, which required the computation of a
numerical score (without absolute risks), we derived and
externally validated an electronic version with absolute
percentage risks. This is suitable for use in hand-held
electronic devices and smartphones, and the clinical
applicability is broadened by using substitutions for cre-
atinine and Killip class. Creatinine values may only be
available after hospital admission and many settings do
not routinely use Killip class for evaluating heart failure
symptoms. Thus, the aim of this study was to develop a
simpliﬁed risk score suitable for applications in a variety
of settings and to test the accuracy of the revised GRACE
risk predictor (GRACE score 2.0) to predict early and
long-term risk, as an aid to clinical management.
METHODS
GRACE risk score
The GRACE registry was designed to reﬂect an unbiased
population of patients with ACS and was undertaken
over 10 years, in 94 hospitals and 14 countries.5 6 18–20
The design has been reported previously.18 20
In-hospital and up to 6 months outcomes and risk
scores were derived based on independent predictors of
outcome. These have been described previously (ST
segment deviation, age, heart rate, systolic blood pres-
sure, creatinine, Killip class, cardiac arrest at admission
and elevated biomarkers of necrosis).5 6 The GRACE
risk score was derived from the original population of
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26 267 patients (11 389 for hospital score for patients
enrolled through 31 March 2001; 21 688 were used to
derive the 6-month risk score for patients enrolled
through 30 September 2002) with suspected ACS, vali-
dated prospectively in a further set of 22 122 patients
and validated externally.5
Risk characteristics of populations may evolve over time
(as management changes) and it is appropriate that the
GRACE score should be tested in a more recent cohort of
patients with ACS and with extended follow-up.21
The original GRACE score was estimated in hospital risk
of death or the combination of death or MI and the same
outcomes up to 6 months postdischarge. The new version
of the GRACE risk score for 1-year outcomes was derived
in the more recent dataset of 32 037 patients from the
GRACE registry enrolled between January 2002 and
December 2007. For three 3-year mortality, the UK cohort
of 1274 patients with long-term follow-up was employed.
The characteristics of this study population have been
reported previously.20 The algorithm employed the same
independent predictors of outcome as originally derived
and reported, but non-linear associations were incorpo-
rated to improve model discrimination. In addition, a sim-
pliﬁed version of the risk score was developed with
substitutions for creatinine (history of renal dysfunction)
and substitutions for Killip class (diuretic usage). As previ-
ously validated, a parsimonious model of only eight factors
conveyed more than 90% of the predictive accuracy of the
complete multivariable model.5 6
Consistency of estimates in different GRACE risk models
The GRACE risk score V.2.0 contains slightly more precise
estimates of V.1.0 hospital6 and 6-month death5 probabil-
ities. Instead of converting model estimates to a point
system, and using intervals for continuous variables such as
age, as in V.1.0, V.2.0 directly utilises model estimates them-
selves to compute cumulative risk (see: http://www.
outcomes-umassmed.org/grace/ﬁles/GRACE_RiskModel_
Coefﬁcients.pdf).
Because GRACE models were derived in different
patient populations from different study periods, differ-
ences in cumulative rate estimates for the same interval
exist. The 1-year death model contains the most recent
and largest patient populations. Therefore, 6-month and
3-year death models were standardised to conform to
estimated Kaplan-Meier cumulative rates for the 1-year
model. The revised V.2.0 6 month cumulative estimates
now conform to V.2.0 1-year model estimates as of
6 months, and the 1-year estimates for the V.2.0 3-year
model as of 1 year also conform to V.2.0 1-year estimates
for the 1-year model.
External validation
The updated GRACE risk score was validated by testing
the algorithm in its full version and simpliﬁed version in
an entirely separate registry population, the French regis-
try of Acute ST-elevation and non-ST-elevation
Myocardial Infarction (FAST-MI).22–24 FAST-MI 2005 is a
nationwide French registry conducted over a 1-month
period at the end of 2005 and it included 3059 patients
with ST segment elevation myocardial infarction
(STEMI) or non-STEMI from 223 centres. Follow-up was
conducted by a research team from the Société Française
de Cardiologie and investigators.22 23 Sequentially, they
consulted death registry data, wrote to family doctors
and/or cardiologists and wrote to patients. In many
instances, written contact was followed by telephone
interviews.22 23 All variables required to calculate the new
GRACE risk score were available in 2959 of the 3059
patients (96.7% of the full cohort). The GRACE algo-
rithm was applied to the 2959 patients using logistic
regression and the c statistics calculated for mortality at
1 year, mortality at 3 years and then for the subsets of
patients with STEMI and non-STEMI. In addition, c statis-
tics were calculated for death or MI. The same analyses
were then repeated for hospital survivors only (n=2806).
In addition, goodness of ﬁt was tested using the
Hosmer-Lemeshow test. Likewise, the simpliﬁed score
was tested in the 3035 patients in whom all variables
needed for its calculation were available.
Statistics
The Kaplan-Meier method was used to estimate 1-year
and 3-year outcome rates.
Cox multiple regression models were ﬁtted to out-
comes of death and death or MI within 1 and 3 years of
hospital admission.24 The same eight factors used in the
original GRACE risk scores were used.6 The method of
restricted cubic splines25 employs a smooth polynomial
function and was used to test for possible non-linear asso-
ciations between outcomes and age, creatinine, pulse and
systolic blood pressure. Also, Killip class using four cat-
egories was compared with linear Killip class. Associations
that improved model likelihood at the α=0.05 level were
retained in ﬁnal models. Such associations were also
plotted and examined for clinical plausibility.
Model performance was evaluated using the May-
Hosmer goodness of ﬁt test,26 and Harrell’s c index for
model discrimination.27 A prediction tool based on
these models uses point estimates and baseline survival
to arrive at predicted outcomes for a given patient’s cov-
ariate experience.28 Plots of estimated model event prob-
abilities for non-linear covariates were produced using
baseline survival estimates and risk factor parameter esti-
mates (on the log hazard scale), evaluated at covariate
means. These plots describe the shape of the association
between the non-linear factors and outcomes, but they
do not substitute for entering all of the patient’s risk
factor information into the risk tool.
RESULTS
Patient characteristics
For the 32 037 patients from the GRACE registry
(table 1), there were 2422 deaths within 365 days of
initial admission, and complete covariate data. The
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distribution of deaths was as follows: 1275 in hospital
(53%), 983 deaths after discharge within 180 days of
admission (41%), 164 deaths from 181–365 days after
admission (7%). The estimated 365 day cumulative
death rate is 9.3% using the Kaplan-Meier method.
For the 3-year model derived from 1274 patients from
the UK, there were 261 deaths: 59 in-hospital (23%), 51
after discharge within 180 days of admission (20%) and
151 in the remaining 2.5 years since admission (58%).
The estimated 3-year cumulative death rate is 20.5%.
Table 1 Characteristics on admission of the GRACE patients with ACS used in 1-year death model and the FAST-MI
patients
GRACE FAST-MI 2005
Demographics
Age (years) 66.6 (56.0–76.4) 68.5 (55.9–78.6)
Female 33% 31%
Weight, kg 78 (68–89) 75 (65–85)
Height, cm 170 (162–175) 169 (162–175)
BMI, kg/m2 27 (24–30) 26 (24–29)
Medical history (%)
Angina 44 30
Atrial fib 7.7 NA
CABG 13 5
Congestive heart failure 10 6
Diabetes 26 24
Dyslipidemia 51 47
Hypertension 64 57
MI 30 17
PCI 19 13
Peripheral arterial disease 9.0 9
Renal insufficiency 7.6 5
Smoking 57 53
Stroke 8.5 6
Presentation characteristics
Pulse, BPM 76 (65–90) 77 (66–90)
DBP, mm Hg 80 (70–90) 80 (70–90)
SBP, mm Hg 140 (120–160) 140 (120–158)
Killip class I 85% 77%
Killip class II 11% 113%
Killip class III 3.6% 8%
Killip class IV 0.8% 2%
Cardiac arrest 1.9% 1.7%
Initial cardiac enzymes positive 52% 100%
Initial serum creatinine, mg/dL 1.02 (0.90–1.25) 1.02 (0.85–1.23)
Electrocardiographic findings (%)
ST-segment elevation 36 50
ST-segment depression 32 22
ST-segment deviation 53 72
T wave inversion 25 10
ST-segment elevation anterior 16 21
ST-segment elevation inferior 18 27
ST-segment depression anterior 15 NA
ST-segment depression inferior 9.2 NA
Any significant Q wave 19 12
Left bundle branch block 4.7 3.9
Prior use of medical therapy (%)
Aspirin 40 24
ACE inhibitors 30 19
Statins 32 27
3307 missing weight, 6098 missing height, 6732 missing BMI; no other variable missing >300. Median (IQR) if continuous variable; per cent if
discrete.
ACS, acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; FAST-MI,
French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction; GRACE, Global Registry of Acute Coronary Events; NA, not
applicable; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
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Performance of the model using non-linear functions
Analyses were undertaken ﬁrst using categorical vari-
ables and linear associations for continuous variables
and Killip class (as in the original description of the
GRACE risk score),5 6 and then using non-linear associa-
tions for age, heart rate, systolic blood pressure and cre-
atinine (ﬁgure 1A–D). Differences were observed
between the non-linear and the linear model with the
former more likely to classify patients as at high risk
(data not shown).
Non-linear associations for the 1-year mortality model
were found for all four continuous measures: systolic
blood pressure, pulse, age and creatinine (p<0.001 vs
linear). The restricted cubic spline (polynomial curve)
functions for age and systolic blood pressure had three
knots (‘inﬂection points’) at the 10th, 50th and 90th
centiles of their distributions, and four knots at the 5th,
35th, 65th and 95th centiles of pulse and creatinine dis-
tributions. HR estimates are reported for selected
intervals, to provide a sense of how associations change
over covariate ranges (table 2). Killip class is modelled
as four distinct groups (p<0.001 vs linear class). The
1-year death/MI model has similar non-linear associa-
tions, while the 3-year death model has four knot cubic
spline associations for systolic blood pressure and pulse
and linear associations for the remaining factors. Also
shown are estimates for the substitute factors of renal
insufﬁciency and diuretics, which can be used to replace
creatinine and Killip when they are unavailable. Sample
sizes increase somewhat for models using the substitute
factors, and model discrimination is only slightly
diminished.
The goodness of ﬁt test is partly a function of sample
size with larger sample sizes increasing the chance that a
small difference between observed and expected
numbers of death will be detected. This was observed,
with differences mainly in the 9th risk decile, (the
model predicted a 3-year risk of 17%, estimated
Figure 1 Non-linear associations for the 1 year mortality model were found for four continuous measures: systolic blood
pressure (A), pulse (B), age (C) and creatinine (figure 1D); p<0.001 vs linear for each comparison.
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observed death 19.5%). The largest difference in the
remaining deciles is 1.2%.
Based on the relative model χ2 values, age is the most
important factor in all three models, followed by systolic
blood pressure, creatinine and Killip class in the 1-year
model (all have similar χ2 values), creatinine and Killip
class in the 1-year death/MI model, and systolic blood
pressure and pulse in the 3-year death model. All models
show good discrimination (c indices ≥0.74), although
combining MI with death in the 1 year model reduces
model discrimination, because death and MI are not
interchangeable with respect to patient risk proﬁles.
External validation of the non-linear GRACE risk score in
the FAST-MI 2005 registry
The characteristics of the FAST-MI 2005 registry are
reﬂective of the range of patients presenting with ACS
(mean age 66.9 years±SD 14.4 years, 31% women, 53%
STEMI, 47% non-STEMI, history of coronary artery
disease 30%, history of stroke 5%, documented diabetes
mellitus 24%, documented hypertension 57%, current
smoking 30% and documented hypercholesterolaemia
47.5%). The FAST-MI 2005 registry has excellent com-
pleteness of follow-up (3-year follow-up 98% complete).
Overall survival was 79% and infarct-free survival was
73%.
Using the FAST-MI 2005 cohort of 2959 patients, c-
statistics for death exceeded 0.82 for the overall popula-
tion at 1 year and also at 3 years (table 3).
Discrimination for death in the model was higher in the
ST-elevation MI population (c=0.84) at 1 year compared
to the non-STEMI population (c=0.80). Discrimination
for death or MI was slightly lower than for death alone
(c=0.78) both at 1 and 3 years. Similar ﬁgures were
obtained for hospital survivors (see tables 3 and 4).
The c-statistics for 3-year death were calculated using
the same approach for the whole ACS population and at
3 years were 0.82 for death and 0.75 for death or MI.
The c indices using the simpliﬁed GRACE model with
substitutions for Killip class and serum creatinine were
available for 99.2% of patients; these were 0.82 for both
1 and 3-year models).
Table 2 Summary of Cox regression models
Admission to 1-year
death
Admission to 1-year death
or MI
Admission to 3 year
death
Total number of observations 32 037 32 037 1274
Number of outcomes 2422 3655 261
May-Hosmer goodness of model fit (P) <0.001 0.06 0.60
Harrell’s c index 0.829 0.746 0.782
Model estimates HR (95% CI), χ2
Age per 10 year
<67 1.5 (1.4 to 1.7), 1069 1.2 (1.1 to 1.3), 853 1.8 (1.6–2.1), 102
≥67 1.9 (1.8 to 2.0) 1.6 (1.5 to 1.6) NA (linear)
Systolic blood pressure per −20 mm Hg ≥139: 1.1 (1.0 to 1.2),
293
≥139: 1.0 (1.0 to 1.1), 200 ≥160: 0.9 (0.7–1.1), 36
<139: 1.3 (1.3 to 1.4) <139: 1.3 (1.2 to 1.3) 130–159: 1.6 (1.2–2.0)
<130: 1.3 (1.0–1.6)
Pulse per 30 BPM
<51 1.1 (0.9 to 1.4), 131 1.0 (0.9 to 1.3), 126 1.0 (0.3 to 2.7), 32
51–83 1.5 (1.4 to 1.7) 1.4 (1.2 to 1.5) 1.7 (1.1 to 2.8)
84–118 1.3 (1.2–1.4) 1.2 (1.2–1.3) 1.6 (1.2 to 2.0)
>118 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0) 0.9 (0.6 to 1.1)
Creatinine per mg
<1 0.6 (0.4 to 1.0), 305 0.9 (0.6 to 1.3), 338 1.5 (1.3 to 1.8), 23
1–2 2.2 (2.0 to 2.4) 1.9 (1.7 to 2.0) NA (linear)
>2 1.1 (1.1 to 1.2) 1.1 (1.1 to 1.2) NA (linear)
Killip class II (v I) 1.9 (1.7 to 2.1), 305 1.7 (1.6 to 1.9), 288 1.1 (0.8 to 1.4), 18
Killip class III (v I) 2.4 (2.1 to 2.7) 2.0 (1.8 to 2.2) III–IV v I: 2.3 (1.6 to
3.4)
Killip class IV (v I) 3.7 (3.0 to 4.5) 3.2 (2.6 to 3.9) NA
Cardiac arrest at admission 2.4 (2.0 to 2.9), 74 2.0 (1.7 to 2.3), 55 2.9 (1.7 to 5.2), 14
Positive initial enzymes 1.5 (1.3 to 1.6), 72 1.3 (1.2 to 1.4), 42 NA
ST deviation 1.6 (1.4 to 1.7), 109 1.4 (1.3 to 1.5), 92 1.5 (1.2 to 1.9), 10
Substitute factors*: renal insufficiency 1.6 (1.4 to 1.7), 66 1.6 (1.5 to 1.8), 105 2.0 (1.3 to 3.2), 9
Diuretics in first 24 h 2.0 (1.8 to 2.1), 266 1.7 (1.6 to 1.8), 236 2.0 (1.5 to 2.6), 27
*Renal insufficiency substituted for creatinine, diuretics for Killip class; sample sizes increase to 33 890 patients with 2585 deaths within a
year of admission (c index 0.820), 33 890 patients with 3882 deaths or MIs within a year of admission (c index 0.738), 1298 patients with 266
deaths within 3 years of admission (c index 0.780).
BPM, beats per minute; NA, not applicable.
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In summary, use of non-linear functions for continu-
ous variables improved model performance over the ori-
ginal GRACE risk score using linear functions. The
external validation demonstrated good model discrimin-
ation at 1 and 3 years for both death and death or MI,
and in subtypes of MI, ST-elevation and non-ST-elevation
MI. This has not been tested previously. The risk score
performs similarly when considering only the survivors
of hospitalisation. The simpliﬁed risk score using a
history of renal dysfunction in place of creatinine values,
and using of diuretics in place of Killip class, performed
almost as well as the full GRACE score.
DISCUSSION
This study aimed to develop an improved version of the
GRACE risk predictor (GRACE score 2.0) incorporating
non-linear associations between continuous risk factors
and outcomes in a format suitable for ease of use in
hand-held electronic devices and smartphones
(ﬁgure 2). In addition, the revised GRACE risk score
allows readily available substitutions for missing variables
at the time of ﬁrst patient presentation (creatinine,
Killip score), and this allows the healthcare professional
to risk score a more complete range of patients hospita-
lised with ACS. The score is not dependent on key vari-
ables—it allows ﬂexibility in light of data availability.
Further, the GRACE score had not been tested for pre-
dictive accuracy beyond 6 months, and the simpliﬁed
version of the risk score with substitutions for creatinine
and for Killip class had not been tested in an independ-
ent population. A key ﬁnding is that model likelihood
using individual non-linear functions for heart rate, sys-
tolic blood pressure, age and creatinine was signiﬁcantly
improved over a model using linear functions for these
factors. In brief, the model with non-linear functions
matches observed data more closely. Further, the
updated GRACE risk score demonstrated similar high
model discrimination at 1 and 3 years as had previously
been demonstrated for in-hospital outcomes and out-
comes to 6 months. In addition, the reduced version of
the GRACE risk score, with substitutions for creatinine
and Killip class (with a history of renal dysfunction and
use of diuretics, respectively), performs nearly as well as
the model with original factors.
What are the implications?
In a diverse range of hospitals in 14 countries worldwide,
with on-site angiographic facilities, the frequency of cathe-
terisations and percutaneous coronary interventions (PCI)
exhibited a paradoxical pattern, whereby most interven-
tions were performed in low-risk rather than high-risk
patients (the ‘treatment-risk paradox’).15 16
To counter the criticism that not all high-risk patients
will be suitable for revascularisation, we undertook
further analyses in a previous publication according to
the frequency of angiography (hospitals with on-site
angiographic facilities were divided into tertiles accord-
ing to the rate of coronary angiography).15 Hospitals with
a high rate of coronary angiography performed substan-
tially more interventions in higher risk patients than
those performed in low rate hospitals, despite a similar
range of risks to patients, demonstrating that these
patients were amenable to the intervention procedures.15
It is possible to estimate the ‘deﬁcit’ in the frequency
of revascularisation based on the actual differences
between high rate and low rate hospitals observed in the
GRACE programme. From the overall population, 37.8%
of patients were in the GRACE high-risk group, 36.1% in
the GRACE medium risk group and 26.1% in the
GRACE lower risk group (categories according to the
ESC guidelines).3 As previously reported,15 individuals
in the highest third of the GRACE risk score had cath-
eterisation performed in 51% and PCI or coronary
artery bypass grafting (CABG) in 31.4% of patients,
whereas those in the medium GRACE risk group had
catheterisation performed in 68% and PCI or CABG in
42.9% and those in the lower risk group had catheterisa-
tion in 72% and PCI or CABG in 47.6%.
Taking the performance of hospitals that were in the
highest third for the rate of coronary angiography (they
performed PCI and CABG in 60.2% of the presenting
population), it is possible to calculate the deﬁcit com-
pared with the hospitals with the lowest rate of angiog-
raphy and revascularisation. The calculation assumes
that the low performance hospitals increased their rate
of PCI and CABG to the same extent as was observed in
the highest third of hospitals. This projection is based
on observed performance data for the rate of angiog-
raphy. The calculation assumes that no more PCI or
CABG was performed than was observed in the high
Table 3 The full GRACE risk score tested in FAST-MI 2005
From ACS
presentation
Overall population (death),
n=2959
STEMI (death),
N=1558
Non-STEMI (death),
N=1401
Overall death/
MI
1-year death 0.83 0.84 0.82 0.77
3-year death 0.82 0.82 0.82 0.77
Hospital survivors n=2806 N=1472 N=1334
1-year death 0.81 0.82 0.80 0.73
3-year death 0.80 0.80 0.80 0.75
ACS,acute coronary syndrome; GRACE, Global Registry of Acute Coronary Events; FAST-M, STEMI,ST segment elevation myocardial
infarction.
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rate hospitals. In brief, 700 more patients per 10 000
would undergo revascularisation if the same patients
presented to high performance hospitals.
The impact of revascularisations on outcomes can be
estimated from the pooled analysis of all the randomised
trials where patients were randomised to an interven-
tional strategy as a routine, or to a selective strategy
based on symptoms and ischaemia.29 We previously
reported this combined analysis based on individual
patient data from the FRISC-2,30 RITA-331 and ICTUS32
trials, and the absolute reduction in cardiovascular
deaths and MIs was 11.1 per 100 patients in the highest
risk group and 4 per 100 in the medium risk group,
over 5 years.29–32 Thus, based on the impact of a system-
atic interventional strategy in the randomised trials,
there would be between 30 and 80 fewer cardiovascular
deaths or MIs for each 10 000 patients with
non-ST-elevation ACS. The estimate is conservative as it
excludes the impact on medium risk patients and the
number would be higher if the top quintile of perform-
ance was used as the reference standard rather than the
top tertile. Thus, consistent with the guideline recom-
mendations, a systematic approach for evaluating risk
has the potential to increase the rate of revascularisation
in high-risk patients without contraindications. Based on
the combined analysis of all the randomised trials with
long-term outcomes, this risk-related strategy has the
potential to reduce the frequency of cardiovascular
death and MI over the longer term. The ‘High’,
‘Medium’ and ‘Low’ risk categories may help guide prac-
tice decisions and they correspond with categories used
by the ESC guidelines.3 However, for more precise esti-
mates, the GRACE risk score also provides the numerical
risk of death (or death/MI) at various time points.
Strengths and limitations
Recognising that population characteristics may differ in
comparison with that of the originally derived GRACE
model, we employed the most recent GRACE dataset in
this study and externally validated the risk model in an
entirely separate dataset (FAST-MI 2005 with yearly
follow-up to 2010). We have previously reported that the
GRACE risk prediction is not subject to signiﬁcant
change over time.33 The purpose of providing 1 and
3-year risk estimates was to aid the clinician regarding
secondary prevention.34 The risk prediction estimates at
3 years were consistent with those at 1 year (although
the 3-year data derive from a smaller dataset).
Figure 2 Illustration of the Global Registry of Acute Coronary Events (GRACE) Score 2.0 on a mobile device (suitable for use in
iOS, android or web versions). Left panel: values for percentage risk of death or death/myocardial infarction (or numerical
GRACE Score). Remaining panels show the individual patient results as a vertical column superimposed on the entire acute
coronary syndrome distribution curve (green column=low risk illustration, yellow column=medium risk and red column=high
risk).34 For further information see http://www.gracescore.co.uk and http://www.outcomes.org/grace.
Table 4 The simplified GRACE risk score, with substitutions for Killip and creatinine (n=3035), tested in FAST-MI 2005
From ACS
presentation
Overall population (death)
N=3035
STEMI (death)
N=1596
Non-STEMI (death)
N=1439
Overall death/
MI
1-year death 0.82 0.84 0.80 0.80
3-year death 0.82 0.83 0.82 0.78
Hospital survivors N=2872 N=1504 N=1368
1-year death 0.80 0.83 0.78 0.74
3-year death 0.81 0.80 0.80 0.76
ACS, acute coronary syndrome; GRACE, Global Registry of Acute Coronary Events; FAST-MI, French registry of Acute ST-elevation and
non-ST-elevation MI; STEMI, ST segment elevation myocardial infarction.
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The GRACE programme is the largest multinational
programme in acute coronary artery disease and was
designed to ensure that the included patients were
reﬂective of the broad spectrum of patients presenting
with ACS, as well as of the range of hospitals in clinical
practice. The sites were trained, audited and quality
control measures were enacted throughout the study.
Use of the UK cohort allowed estimation of long-term
outcomes (as previously reported) with complete mortal-
ity data to 5 years.20 The external validation of the
updated risk score was performed in the FAST-MI 2005
registry with inclusion of the full spectrum of hospitals
admitting patients with ACS and excellent completeness
of follow-up.
Although the updated GRACE risk score provides a
reliable estimate for stratifying patients both acutely and
in the long term, additional factors contribute to longer
term risk. Further reﬁnement of the risk score for long-
term outcomes may require the inclusion of additional
risk factors and biomarkers to increase precision, but
the current risk score discrimination allows separation of
patients into broad categories relevant for decisions on
clinical management. Future studies will determine the
impact of risk scoring strategies in various populations
including the frail and elderly.
CONCLUSIONS
The updated GRACE risk score has better model dis-
crimination and is easier to use than previous scores
based on categorical variables. It is accurate in the acute
phase and over the longer term and can be used in a
variety of clinical settings to aid management decisions.
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